Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial.
作者信息
Bucci Enrico M, Berkhof Johannes, Gillibert André, Gopalakrishna Gowri, Calogero Raffaele A, Bouter Lex M, Andreev Konstantin, Naudet Florian, Vlassov Vasiliy
机构信息
Sbarro Institute, Temple University Department of Biology, Philadelphia, 19122 PA, USA.
Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.
出版信息
Lancet. 2021 May 22;397(10288):1881-1883. doi: 10.1016/S0140-6736(21)00899-0. Epub 2021 May 12.
Abstract
摘要
相似文献
1
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial.卫星V 3期试验中期数据的数据差异及报告不达标
Lancet. 2021 May 22;397(10288):1881-1883. doi: 10.1016/S0140-6736(21)00899-0. Epub 2021 May 12.
2
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.卫星V 3期试验中期数据的数据差异和报告不规范——作者回复
Lancet. 2021 May 22;397(10288):1883-1884. doi: 10.1016/S0140-6736(21)00894-1. Epub 2021 May 12.
3
Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.俄罗斯卫星 V 疫苗的轻度不良反应：通过深度学习对电报的社交媒体内容分析。
J Med Internet Res. 2021 Nov 29;23(11):e30529. doi: 10.2196/30529.
4
BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.BNT162b2、mRNA-1273 和 Sputnik V 疫苗在诱导免疫应答方面可相媲美，可预防 COVID-19 重症。
Front Immunol. 2022 Apr 13;13:797918. doi: 10.3389/fimmu.2022.797918. eCollection 2022.
5
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance.罗卡观察性研究：在圣马力诺共和国使用主动监测对卫星五号疫苗（Gam-COVID-Vac）安全性的早期结果。
EClinicalMedicine. 2021 Jul 8;38:101027. doi: 10.1016/j.eclinm.2021.101027. eCollection 2021 Aug.
6
Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance.在德尔塔变异株占主导期间，接种卫星V轻型疫苗和卫星V疫苗能有效保护医护人员免受新冠病毒感染。
Vaccines (Basel). 2022 Oct 26;10(11):1804. doi: 10.3390/vaccines10111804.
7
Kinetics of Antibody Response to Repeated Vaccination with Sputnik V: A Pilot Study with a Series of Five Cases.对卫星五号疫苗重复接种的抗体反应动力学：一项包含五例病例的系列初步研究
EJIFCC. 2022 Aug 8;33(2):175-186. eCollection 2022 Aug.
8
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
9
International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.ABVD 治疗的晚期霍奇金淋巴瘤中 PET 中期评估的国际验证研究：解读标准和评审者之间的一致性。
J Nucl Med. 2013 May;54(5):683-90. doi: 10.2967/jnumed.112.110890. Epub 2013 Mar 20.
10
Adverse effects following COVID-19 vaccination in Iran.伊朗 COVID-19 疫苗接种的不良反应。
BMC Infect Dis. 2022 May 18;22(1):476. doi: 10.1186/s12879-022-07411-5.
引用本文的文献
1
Determinants of COVID-19 Vaccine Uptake Among People Living with Human Immunodeficiency Virus.感染人类免疫缺陷病毒者中COVID-19疫苗接种率的决定因素
J Int Assoc Provid AIDS Care. 2025 Jan-Dec;24:23259582251328861. doi: 10.1177/23259582251328861. Epub 2025 Apr 1.
2
How prevalent is COVID-19 vaccine hesitancy in low-income and middle-income countries and what are the key drivers of hesitancy? Results from 53 countries.在低收入和中等收入国家，对 COVID-19 疫苗的犹豫态度有多普遍，其主要驱动因素是什么？来自 53 个国家的结果。
BMJ Open. 2023 Nov 6;13(11):e069152. doi: 10.1136/bmjopen-2022-069152.
3
Development of Peptic Ulcer following Second Shot of Sputnik V Vaccine: A Case Report and Literature Review of Rare Side Effects of Sputnik V Vaccine.接种第二剂卫星五号疫苗后发生消化性溃疡：一例病例报告及卫星五号疫苗罕见副作用的文献综述
Case Rep Infect Dis. 2023 Sep 21;2023:9989515. doi: 10.1155/2023/9989515. eCollection 2023.
4
Adverse events following immunisation with the first dose of sputnik V among Iranian health care providers.伊朗医护人员接种第一剂卫星五号疫苗后的不良事件。
Clin Exp Vaccine Res. 2023 Jan;12(1):25-31. doi: 10.7774/cevr.2023.12.1.25. Epub 2023 Jan 31.
5
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
6
Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.俄罗斯圣彼得堡在德尔塔变异株流行期间，针对感染 SARS-CoV-2 后转诊至医院的疫苗效力：一项病例对照研究。
BMC Med. 2022 Sep 20;20(1):312. doi: 10.1186/s12916-022-02509-8.
7
COVID-19: The question of genetic diversity and therapeutic intervention approaches.新冠病毒：基因多样性与治疗干预方法问题
Genet Mol Biol. 2022 Apr 8;44(1 Suppl 1):e20200452. doi: 10.1590/1678-4685-GMB-2020-0452. eCollection 2021.
8
Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Restimulation.卫星五号疫苗接种诱导的记忆 B 细胞在再刺激时产生针对 SARS-CoV-2 的中和抗体。
Front Immunol. 2022 Feb 24;13:840707. doi: 10.3389/fimmu.2022.840707. eCollection 2022.
9
Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.俄罗斯卫星 V 疫苗的轻度不良反应：通过深度学习对电报的社交媒体内容分析。
J Med Internet Res. 2021 Nov 29;23(11):e30529. doi: 10.2196/30529.
10
The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.接种基于腺病毒载体的SARS-CoV-2疫苗后疫苗诱导的免疫性血栓性血小板减少症的临床关联
Immunother Adv. 2021 Aug 17;1(1):ltab019. doi: 10.1093/immadv/ltab019. eCollection 2021 Jan.
本文引用的文献
1
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
2
Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.俄罗斯新冠疫苗的安全性与有效性：仍需更多信息——作者回复
Lancet. 2020 Oct 3;396(10256):e54-e55. doi: 10.1016/S0140-6736(20)31970-X. Epub 2020 Sep 21.
3
Safety and efficacy of the Russian COVID-19 vaccine: more information needed.俄罗斯新冠疫苗的安全性与有效性：尚需更多信息。
Lancet. 2020 Oct 3;396(10256):e53. doi: 10.1016/S0140-6736(20)31960-7. Epub 2020 Sep 21.
4
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.两种配方的基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和免疫原性：来自俄罗斯的两项开放、非随机的 1/2 期研究。
Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4.
Zotero 插件